CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results

Rhea-AI Summary

CONMED (NYSE: CNMD) reported its Q4 and full-year 2024 financial results. In Q4, sales reached $345.9 million, up 5.8% year-over-year, with domestic revenue increasing 6.8% and international revenue growing 4.4%. Q4 GAAP earnings per share were $1.08, while adjusted EPS reached $1.34, up 26.4% from Q4 2023.

For full-year 2024, sales totaled $1,307.0 million, a 5.0% increase, with domestic revenue up 6.9% and international revenue rising 2.6%. Full-year GAAP EPS was $4.25, with adjusted EPS at $4.17, up 20.9% from 2023.

Looking ahead to 2025, CONMED projects revenue between $1.344-1.372 billion, representing 4-6% constant currency growth, and adjusted EPS of $4.25-$4.40, factoring in currency headwinds but excluding potential tariff impacts.

Positive

• Q4 sales increased 5.8% to $345.9 million
• Q4 adjusted EPS grew 26.4% to $1.34
• Full-year sales rose 5.0% to $1.307 billion
• Full-year adjusted EPS increased 20.9% to $4.17
• Domestic revenue growth outpaced international in both Q4 and full-year

Negative

• Persistent supply challenges affected business performance
• Expected currency headwinds of $0.15-$0.20 for 2025
• Potential impact from new tariffs not included in guidance

Insights

Financial Analyst

CONMED's Q4 and FY2024 performance reveals a company successfully navigating operational headwinds while delivering profitable growth. The 26.4% jump in Q4 adjusted EPS significantly outpaced revenue growth of 5.8%, indicating substantial margin expansion and operational efficiency improvements.

The domestic market remains the growth engine, with 6.8% Q4 revenue growth outperforming international markets. This geographic disparity suggests potential opportunities for international market optimization, particularly given the projected currency headwinds of 100-120 basis points for 2025.

The 2025 guidance presents a measured outlook with 4-6% constant currency growth, notably lower than 2024's performance. The $0.15-$0.20 expected currency headwind on EPS is significant, representing approximately 4% of projected earnings. The explicit mention of excluding potential tariff impacts adds an element of uncertainty to the forecast.

Most telling is management's focus on operational improvements for 2025, suggesting internal recognition of efficiency opportunities. The supply challenges mentioned likely impacted inventory management and working capital efficiency, areas where improvements could drive additional value in 2025.

The projected adjusted EPS growth from $4.17 to $4.25-$4.40 represents a modest 2-5.5% increase, indicating potential margin pressure or conservative guidance. This cautious outlook, combined with operational focus, suggests management is prioritizing sustainable growth over aggressive targets.

LARGO, Fla.--(BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024.

Fourth Quarter 2024 Highlights

• Sales of $345.9 million increased 5.8% year over year as reported and 6.0% in constant currency.
• Domestic revenue increased 6.8% year over year.
• International revenue increased 4.4% year over year as reported and 5.0% in constant currency.
• Diluted net earnings per share (GAAP) were $1.08 compared to diluted net earnings per share (GAAP) of $1.05 in the fourth quarter of 2023.
• Adjusted diluted net earnings per share⁽¹⁾ were $1.34, an increase of 26.4% compared to the fourth quarter of 2023.

Full-Year 2024 Highlights

• Sales of $1,307.0 increased 5.0% year over year as reported and 5.3% in constant currency.
• Domestic revenue increased 6.9% year over year.
• International revenue increased 2.6% year over year as reported and 3.4% in constant currency.
• Diluted net earnings per share (GAAP) were $4.25 compared to diluted net earnings per share (GAAP) of $2.04 in 2023.
• Adjusted diluted net earnings per share⁽¹⁾ were $4.17, an increase of 20.9% compared to 2023.

“2024 was a year of solid sales and earnings growth but was also challenging as we navigated persistent supply challenges for parts of our business. I am pleased with our progress in the fourth quarter, particularly with respect to our improved profitability,” commented Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “In 2025, we are laser focused on improving our operations and strengthening our foundation for future above-market revenue and profitability growth.”

2025 Outlook

The Company expects full-year 2025 reported revenue between $1.344 billion and $1.372 billion. This represents year over year constant currency growth of approximately 4% to 6% and approximately 100 basis points to 120 basis points of currency headwind.

The Company expects full-year 2025 adjusted diluted net earnings per share⁽²⁾ in the range of $4.25 to $4.40. This includes a currency headwind of approximately $0.15 to $0.20. This guidance excludes any potential impact from the recently announced tariffs.

Supplemental Financial Disclosures

⁽¹⁾ A reconciliation of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

⁽²⁾ Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.

Conference Call

The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its fourth quarter and full-year 2024 results.

To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

Consolidated Condensed Statements of Income
(in thousands except per share amounts, unaudited)
		Three Months Ended								Year Ended
		December 31,								December 31,
			2024				2023				2024				2023
Net sales		$	345,944			$	327,045			$	1,307,015			$	1,244,744
Cost of sales			147,600				144,870				573,983				568,499
Gross profit			198,344				182,175				733,032				676,245
% of sales			57.3	%			55.7	%			56.1	%			54.3	%
Selling & administrative expense			132,669				117,960				478,280				503,040
Research & development expense			13,176				14,028				54,426				52,602
Income from operations			52,499				50,187				200,326				120,603
% of sales			15.2	%			15.3	%			15.3	%			9.7	%
Interest expense			8,857				9,505				37,297				39,775
Income before income taxes			43,642				40,682				163,029				80,828
Provision for income taxes			9,888				7,611				30,606				16,369
Net income		$	33,754			$	33,071			$	132,423			$	64,459
Basic EPS		$	1.09			$	1.08			$	4.29			$	2.10
Diluted EPS			1.08				1.05				4.25				2.04
Basic shares			30,923				30,759				30,846				30,668
Diluted shares			31,146				31,502				31,150				31,548

Sales Summary
(in millions, unaudited)
	Three Months Ended December 31,
								% Change
															Domestic			International
		2024			2023			As Reported		Impact of Foreign Currency		Constant Currency			As Reported			As Reported		Impact of Foreign Currency		Constant Currency
Orthopedic Surgery	$	139.0		$	136.5			1.8	%	0.6	%	2.4	%		5.2	%		-0.2	%	0.8	%	0.6	%
General Surgery		206.9			190.5			8.6	%	0.1	%	8.7	%		7.4	%		11.9	%	0.1	%	12.0	%
	$	345.9		$	327.0			5.8	%	0.2	%	6.0	%		6.8	%		4.4	%	0.6	%	5.0	%
Single-use Products	$	297.3		$	271.3			9.6	%	0.2	%	9.8	%		7.5	%		13.0	%	0.7	%	13.7	%
Capital Products		48.6			55.7			-12.7	%	0.3	%	-12.4	%		1.8	%		-22.9	%	0.5	%	-22.4	%
	$	345.9		$	327.0			5.8	%	0.2	%	6.0	%		6.8	%		4.4	%	0.6	%	5.0	%
Domestic	$	203.3		$	190.3			6.8	%	0.0	%	6.8	%
International		142.6			136.7			4.4	%	0.6	%	5.0	%
	$	345.9		$	327.0			5.8	%	0.2	%	6.0	%
	Year Ended December 31,
								% Change
															Domestic			International
		2024			2023			As Reported		Impact of Foreign Currency		Constant Currency			As Reported			As Reported		Impact of Foreign Currency		Constant Currency
Orthopedic Surgery	$	544.0		$	533.1			2.0	%	0.5	%	2.5	%		5.6	%		-0.1	%	0.8	%	0.7	%
General Surgery		763.0			711.6			7.2	%	0.3	%	7.5	%		7.4	%		6.9	%	0.7	%	7.6	%
	$	1,307.0		$	1,244.7			5.0	%	0.3	%	5.3	%		6.9	%		2.6	%	0.8	%	3.4	%
Single-use Products	$	1,112.1		$	1,038.5			7.1	%	0.3	%	7.4	%		8.0	%		5.7	%	0.8	%	6.5	%
Capital Products		194.9			206.2			-5.5	%	0.4	%	-5.1	%		-1.0	%		-9.0	%	0.7	%	-8.3	%
	$	1,307.0		$	1,244.7			5.0	%	0.3	%	5.3	%		6.9	%		2.6	%	0.8	%	3.4	%
Domestic	$	748.2		$	700.1			6.9	%	0.0	%	6.9	%
International		558.8			544.6			2.6	%	0.8	%	3.4	%
	$	1,307.0		$	1,244.7			5.0	%	0.3	%	5.3	%

Reconciliation of Reported Net Income to Adjusted Net Income
(in thousands, except per share amounts, unaudited)
	Three Months Ended December 31, 2024
	Gross Profit			Selling & Administrative Expense			Operating Income			Interest Expense			Tax Expense			Effective Tax Rate		Net Income			Diluted EPS
As reported	$	198,344		$	132,669		$	52,499		$	8,857		$	9,888		22.7	%	$	33,754		$	1.08
% of sales		57.3	%		38.3	%		15.2	%
Contingent consideration fair value adjustments(1)		-			(1,219	)		1,219			-			1,058					161
Hurricane impact(2)		955			-			955			-			829					126
Lease impairment(3)		-			(606	)		606			-			526					80
Legal matters(4)		-			(531	)		531			-			461					70
	$	199,299		$	130,313		$	55,810		$	8,857		$	12,762				$	34,191
Adjusted gross profit %		57.6	%
Amortization(5)	$	1,500			(7,162	)		8,662			(1,443	)		2,456					7,649
As adjusted				$	123,151		$	64,472		$	7,414		$	15,218		26.7	%	$	41,840		$	1.34
% of sales					35.6	%		18.6	%
Shares																						31,146
Convertible note hedges(6)																						-
Adjusted diluted shares																						31,146
	Three Months Ended December 31, 2023
	Gross Profit			Selling & Administrative Expense			Operating Income			Interest Expense			Tax Expense			Effective Tax Rate		Net Income			Diluted EPS
As reported	$	182,175		$	117,960		$	50,187		$	9,505		$	7,611		18.7	%	$	33,071		$	1.05
% of sales		55.7	%		36.1	%		15.3	%
Contingent consideration fair value adjustments(1)		-			9,370			(9,370	)		-			703					(10,073	)
Acquisition and integration costs(7)		2,154			-			2,154			-			(162	)				2,316
	$	184,329		$	127,330		$	42,971		$	9,505		$	8,152				$	25,314
Adjusted gross profit %		56.4	%
Amortization(5)	$	1,500			(7,295	)		8,795			(1,500	)		2,458					7,837
As adjusted				$	120,035		$	51,766		$	8,005		$	10,610		24.2	%	$	33,151		$	1.06
% of sales					36.7	%		15.8	%
Shares																						31,502
Convertible note hedges(6)																						(110	)
Adjusted diluted shares																						31,392

(1) In 2024 and 2023, the Company recorded income/(expense) related to the fair value adjustments of contingent consideration.

(2) In 2024, the Company incurred costs due to the impact of Hurricane Milton on our Largo, FL facility. These costs were mainly comprised of emergency pay to employees and plant underutilization due to abnormally low production.

(3) In 2024, the Company recorded lease impairment expense related to a storage facility no longer utilized.

(4) In 2024, the Company incurred costs for third party services pertaining to potential issues with certain royalty payments to design surgeons.

(5) Includes amortization of intangible assets and deferred financing fees.

(6) Non-GAAP adjusted dilutive weighted average shares outstanding exclude dilution that is expected to be offset by the Company’s convertible notes hedge transactions.

(7) In 2023, the Company incurred charges related to the amortization of inventory step-up to fair value associated with the acquisition of In2Bones Global, Inc.

Reconciliation of Reported Net Income to Adjusted Net Income
(in thousands, except per share amounts, unaudited)
Year Ended December 31, 2024
	Gross Profit			Selling & Administrative Expense			Operating Income			Interest Expense			Tax Expense			Effective Tax Rate		Net Income			Diluted EPS
As reported	$	733,032		$	478,280		$	200,326		$	37,297		$	30,606		18.8	%	$	132,423		$	4.25
% of sales		56.1	%		36.6	%		15.3	%
Legal matters(1)		-			(5,097	)		5,097			-			806					4,291
Restructuring and related costs(2)		235			(1,539	)		1,774			-			255					1,519
Asset impairment costs (3)		1,414			-			1,414			-			203					1,211
Hurricane impact(4)		955			-			955			-			829					126
Lease impairment(5)		-			(606	)		606			-			526					80
Termination of distributor agreement(6)		-			970			(970	)		-			(139	)				(831	)
Contingent consideration fair value adjustments(7)		-			41,048			(41,048	)		-			(1,591	)				(39,457	)
	$	735,636		$	513,056		$	168,154		$	37,297		$	31,495				$	99,362
Adjusted gross profit %		56.3	%
Amortization(8)	$	6,000			(28,629	)		34,629			(5,700	)		9,775					30,554
As adjusted				$	484,427		$	202,783		$	31,597		$	41,270		24.1	%	$	129,916		$	4.17
% of sales					37.1	%		15.5	%
Shares																						31,150
Convertible note hedges(9)																						-
Adjusted diluted shares																						31,150

Reconciliation of Reported Net Income to Adjusted Net Income
(in thousands, except per share amounts, unaudited)
Year Ended December 31, 2023
	Gross Profit			Selling & Administrative Expense			Operating Income			Interest Expense			Tax Expense			Effective Tax Rate		Net Income			Diluted EPS
As reported	$	676,245		$	503,040		$	120,603		$	39,775		$	16,369		20.3	%	$	64,459		$	2.04
% of sales		54.3	%		40.4	%		9.7	%
Restructuring and related costs(2)		2,035			(1,578	)		3,613			-			930					2,683
Termination of distributor agreements(6)		-			(2,098	)		2,098			-			417					1,681
Contingent consideration fair value adjustments(7)		-			2,421			(2,421	)		-			2,037					(4,458	)
Acquisition and integration costs(10)		8,617			(752	)		9,369			-			1,207					8,162
Software implementation costs(11)		-			(6,056	)		6,056			-			1,453					4,603
	$	686,897		$	494,977		$	139,318		$	39,775		$	22,413				$	77,130
Adjusted gross profit %		55.2	%
Amortization(8)	$	6,000			(29,068	)		35,068			(6,058	)		9,969					31,157
As adjusted				$	465,909		$	174,386		$	33,717		$	32,382		23.0	%	$	108,287		$	3.45
% of sales					37.4	%		14.0	%
Shares																						31,548
Convertible note hedges(9)																						(142	)
Adjusted diluted shares																						31,406

(1) In 2024, the Company incurred costs for third party services pertaining to potential issues with certain royalty payments to design surgeons.

(2) In 2024, the Company incurred severance costs related to the elimination of certain positions. In 2023, the Company incurred consulting fees related to an operational cost improvement initiative and severance related to the elimination of certain positions.

(3) In 2024, the Company wrote off inventory, tooling and equipment related to the cancellation of a planned new product line.

(4) In 2024, the Company's incurred costs due to the impact of Hurricane Milton on our Largo, FL facility. These costs were mainly comprised of emergency pay to employees and plant underutilization due to abnormally low production.

(5) In 2024, the Company recorded lease impairment expense related to a storage facility no longer utilized.

(6) In 2024, the Company recorded an accrual adjustment related to the previous termination of a distributor agreement. In 2023, the Company incurred costs related to the termination of distributor agreements.

(7) In 2024 and 2023, the Company incurred income/(expense) related to the fair value adjustments of contingent consideration.

(8) Includes amortization of intangible assets and deferred financing fees.

(9) Non-GAAP adjusted dilutive weighted average shares outstanding exclude dilution that is expected to be offset by the Company’s convertible notes hedge transactions.

(10) In 2023, the Company incurred charges related to the amortization of inventory step-up to fair value associated with the acquisition of In2Bones Global, Inc., and integration costs and professional fees associated with the acquisitions of In2Bones Global, Inc. and Biorez, Inc.

(11) In 2023, the Company incurred additional freight, labor and travel costs as well as professional fees related to the implementation of a warehouse management software.

Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA
(in thousands, unaudited)
	Three Months Ended								Year Ended
	December 31,								December 31,
		2024				2023				2024				2023
Net income	$	33,754			$	33,071			$	132,423			$	64,459
Provision for income taxes		9,888				7,611				30,606				16,369
Interest expense		8,857				9,505				37,297				39,775
Depreciation		4,199				4,052				16,605				16,200
Amortization		13,807				13,950				55,252				55,674
EBITDA	$	70,505			$	68,189			$	272,183			$	192,477
Stock based compensation		6,222				5,923				25,558				24,257
Contingent consideration fair value adjustments		1,219				(9,370	)			(41,048	)			(2,421	)
Hurricane impact		955				-				955				-
Lease impairment		606				-				606				-
Legal matters		531				-				5,097				-
Restructuring and related costs		-				-				1,774				3,613
Asset impairment costs		-				-				1,414				-
Termination of distributor agreements		-				-				(970	)			2,098
Acquisition and integration costs		-				2,154				-				9,369
Software implementation costs		-				-				-				6,056
Adjusted EBITDA	$	80,038			$	66,896			$	265,569			$	235,449
EBITDA Margin
EBITDA		20.4	%			20.9	%			20.8	%			15.5	%
Adjusted EBITDA		23.1	%			20.5	%			20.3	%			18.9	%

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2023, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted interest expense; adjusted income tax expense; adjusted effective income tax rate; adjusted net income, adjusted diluted shares and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.

Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, operating income, interest expense, income tax expense, effective income tax rate, net income, diluted shares and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250205642486/en/

CONMED Corporation

Todd W. Garner

Chief Financial Officer

727-214-2975

ToddGarner@conmed.com

Source: CONMED Corporation

FAQ

What was CONMED's (CNMD) Q4 2024 revenue growth?

CONMED's Q4 2024 revenue grew 5.8% year-over-year to $345.9 million, with 6.0% growth in constant currency.

How much did CONMED's (CNMD) adjusted EPS increase in Q4 2024?

CONMED's Q4 2024 adjusted EPS increased 26.4% to $1.34 compared to Q4 2023.

What is CONMED's (CNMD) revenue guidance for 2025?

CONMED expects 2025 revenue between $1.344 billion and $1.372 billion, representing 4-6% constant currency growth.

What are CONMED's (CNMD) projected earnings per share for 2025?

CONMED projects adjusted diluted net earnings per share of $4.25 to $4.40 for 2025, including currency headwinds of $0.15-$0.20.

How did CONMED's (CNMD) domestic revenue perform in 2024?

CONMED's domestic revenue increased 6.9% year-over-year in 2024.